Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris
Status:
Unknown status
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
Tissue inflammation is a major component of the acne disease process. Leukotriene B4 (LTB4)
is thought to be a major player in the development of tissue inflammation. Synthesis of LTB4
is controlled by the enzyme 5-lipoxygenase. Zileuton blocks the activity of 5-lipoxygenase.
This study will test the safety and efficacy of zileuton in the treatment of facial acne.